- Revenue: $3.79B, +10% YoY
- Net income: $918M, -21% YoY
- GAAP EPS: $8.06 vs $10.19 in Q4 2023
- Non-GAAP EPS: $12.07, +2% YoY
CEO Leonard S. Schleifer: "Regeneron's financial and commercial strength allows for continued investment in our industry-leading R&D pipeline, while simultaneously returning capital to our shareholders through our newly initiated dividend program and increased share repurchase capacity."
🌱Revenue & Growth
- EYLEA HD & EYLEA U.S. sales: $1.50B, +2% YoY
- Dupixent global sales: $3.70B, +15% YoY
- Libtayo global sales: $367M, +50% YoY
- Sanofi collaboration revenue: $1.21B, +22% YoY
💰Profits & Financials
- GAAP R&D expenses: $1.41B, +20% YoY
- GAAP gross margin: 84-85%
- Cash and marketable securities: $17.91B
- Share repurchase: $976M in Q4, $2.6B in FY2024
📌Business Highlights
- Initiated quarterly dividend program ($0.88 per share)
- Increased share repurchase capacity to ~$4.5B
- Submitted regulatory applications for EYLEA HD pre-filled syringe, Dupixent in bullous pemphigoid